Artículos de revistas sobre el tema "BRAF35"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "BRAF35".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Rugerio-Martínez, Claudia Ivette, Daniel Ramos, Abel Segura-Olvera, Nadia Mireya Murillo-Melo, Yessica Sarai Tapia-Guerrero, Raúl Argüello-García, Norberto Leyva-García, Oscar Hernández-Hernández, Bulmaro Cisneros y Rocío Suárez-Sánchez. "Dp71 Point Mutations Induce Protein Aggregation, Loss of Nuclear Lamina Integrity and Impaired Braf35 and Ibraf Function in Neuronal Cells". International Journal of Molecular Sciences 23, n.º 19 (6 de octubre de 2022): 11876. http://dx.doi.org/10.3390/ijms231911876.
Texto completoMi LEE, Young y Wankee KIM. "Association of human kinesin superfamily protein member 4 with BRCA2-associated factor 35". Biochemical Journal 374, n.º 2 (1 de septiembre de 2003): 497–503. http://dx.doi.org/10.1042/bj20030452.
Texto completoHakimi, M. A., D. A. Bochar, J. Chenoweth, W. S. Lane, G. Mandel y R. Shiekhattar. "A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes". Proceedings of the National Academy of Sciences 99, n.º 11 (28 de mayo de 2002): 7420–25. http://dx.doi.org/10.1073/pnas.112008599.
Texto completoZanchetta, Melania E., Luisa M. R. Napolitano, Danilo Maddalo y Germana Meroni. "The E3 ubiquitin ligase MID1/TRIM18 promotes atypical ubiquitination of the BRCA2-associated factor 35, BRAF35". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1864, n.º 10 (octubre de 2017): 1844–54. http://dx.doi.org/10.1016/j.bbamcr.2017.07.014.
Texto completoCeballos-Chavez, M., S. Rivero, P. Garcia-Gutierrez, M. Rodriguez-Paredes, M. Garcia-Dominguez, S. Bhattacharya y J. C. Reyes. "Control of neuronal differentiation by sumoylation of BRAF35, a subunit of the LSD1-CoREST histone demethylase complex". Proceedings of the National Academy of Sciences 109, n.º 21 (8 de mayo de 2012): 8085–90. http://dx.doi.org/10.1073/pnas.1121522109.
Texto completoLee, Belinda, Angelyn Anton, Margaret Lee, Rachel Wong, Phillip Parente, Jeremy David Shapiro, Desmond Yip et al. "Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC)." Journal of Clinical Oncology 35, n.º 4_suppl (1 de febrero de 2017): 728. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.728.
Texto completoOsterlund, Pia J., Emerik Osterlund, Aki Uutela, Päivi Halonen, Raija S. Kallio, Annika Ålgars, Tapio Salminen et al. "Resectability, conversion and resections rates, and outcomes in RAS&BRAF wildtype (wt), RAS mutant (mt) and BRAFmt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 3532. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3532.
Texto completoBraithwaite, Matthew, Christopher Duane Nevala-Plagemann, Kelsey Baron, Benjamin Haaland, Lisa M. Pappas y Ignacio Garrido-Laguna. "Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): 4030. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4030.
Texto completoHernandez-Aya, Leonel Fernando, Matthew Burke, Jenna M. Collins, Dennis Earle, Melissa Hamilton, Beth L. Nordstrom, Ying Zhang y Shivani Srivastava. "Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy." Journal of Clinical Oncology 38, n.º 15_suppl (20 de mayo de 2020): e22036-e22036. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22036.
Texto completoTrunk, Andrew, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland y Ignacio Garrido-Laguna. "Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States". Journal of the National Comprehensive Cancer Network 20, n.º 2 (febrero de 2022): 144–50. http://dx.doi.org/10.6004/jnccn.2021.7059.
Texto completoNordstrom, Beth L., Melissa Hamilton, Jenna M. Collins, Dennis Earle, Ying Zhang, Shivani Srivastava y Leonel Hernandez-Aya. "Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma". Future Oncology 18, n.º 11 (abril de 2022): 1343–55. http://dx.doi.org/10.2217/fon-2021-0340.
Texto completoVergidis, Joanna, Richard John Klasa, Youwen Zhou, Elena Moon, Debbie Jepson y Kerry J. Savage. "Outcome and prognostic factors in BRAF mutation positive metastatic melanoma treated with a BRAF inhibitor: A population-based study in British Columbia." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e20045-e20045. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e20045.
Texto completoMa, Michelle W., Joshua Andrew Farhadian, Erica Brooke Friedman, Eleazar Vega-Saenz de Miera, Douglas Hanniford, Miguel F. Segura, Russell S. Berman et al. "MicroRNA alterations associated with BRAF status in melanoma." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 8565. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8565.
Texto completoKarreth, Florian, Markus Reschke, Bjoern Chapuy, Margaret A. Shipp, Roberto Chiarle y Pier Paolo Pandolfi. "The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA". Blood 124, n.º 21 (6 de diciembre de 2014): 263. http://dx.doi.org/10.1182/blood.v124.21.263.263.
Texto completoQiang, Ya-Wei, Shiqiao Ye, Yu Chen, Joshua Epstein, Brian A. Walker, Frits van Rhee, Gareth Morgan y Faith E. Davies. "Mutant KRAS and Brafs Upregulate Stress Granules and Mediate Drug Resistance, Which Can be Modulated By Cox2 Inhibition in Multiple Myeloma". Blood 132, Supplement 1 (29 de noviembre de 2018): 3166. http://dx.doi.org/10.1182/blood-2018-99-117459.
Texto completoDuggan, Megan C., Andrew R. Stiff, Maryam Bainazar, Kelly Regan, Gonzalo N. Olaverria Salavaggione, Sophia Maharry, James S. Blachly et al. "Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma". Proceedings of the National Academy of Sciences 114, n.º 36 (21 de agosto de 2017): 9629–34. http://dx.doi.org/10.1073/pnas.1704371114.
Texto completoXu, Zhiyuan, Cheng-Chia Lee, Arjun Ramesh, Adam C. Mueller, David Schlesinger, Or Cohen-Inbar, Han-Hsun Shih y Jason P. Sheehan. "BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases". Journal of Neurosurgery 126, n.º 3 (marzo de 2017): 726–34. http://dx.doi.org/10.3171/2016.2.jns1633.
Texto completoCybulska-Stopa, Bozena, Anna Malgorzata Czarnecka, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska et al. "Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?" Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e21544-e21544. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21544.
Texto completoCybulska-Stopa, Bozena, Anna Malgorzata Czarnecka, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska et al. "Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?" Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e21544-e21544. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21544.
Texto completoPark, Jongwhi, Hope Lancero, Emon Nasajpour, Cesar Garcia, Laura Prolo, Gerald Grant y Claudia Petritsch. "STEM-15. THERAPY-INDUCED CHANGES BY BRAF AND MEK INHIBITORS IN BRAF V600E-MUTATED GLIOMA MODELS PROVIDE POTENTIAL NOVEL THERAPEUTIC OPPORTUNITIES". Neuro-Oncology 24, Supplement_7 (1 de noviembre de 2022): vii34. http://dx.doi.org/10.1093/neuonc/noac209.132.
Texto completoWichmann, Jürgen, Caroline Rynn, Thomas Friess, Jeannine Petrig-Schaffland, Martin Kornacker, Cornelia Handl, Jasmin Emmenegger et al. "Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor". Clinical Cancer Research 28, n.º 4 (15 de noviembre de 2021): 770–80. http://dx.doi.org/10.1158/1078-0432.ccr-21-2761.
Texto completoGebhardt, Kathleen, Bayram Edemir, Elisabeth Groß, Linda Nemetschke, Stefanie Kewitz-Hempel, Rose K. C. Moritz, Cord Sunderkötter y Dennis Gerloff. "BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma". Cancers 13, n.º 10 (15 de mayo de 2021): 2393. http://dx.doi.org/10.3390/cancers13102393.
Texto completoTanaka, Yuka, Maho Murata, Che-Hung Shen, Masutaka Furue y Takamichi Ito. "NECTIN4: A Novel Therapeutic Target for Melanoma". International Journal of Molecular Sciences 22, n.º 2 (19 de enero de 2021): 976. http://dx.doi.org/10.3390/ijms22020976.
Texto completoMenzer, Christian, Alexander M. Menzies, Matteo S. Carlino, Irene Reijers, Emma J. Groen, Thomas Eigentler, Jan Willem B. de Groot et al. "Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations". Journal of Clinical Oncology 37, n.º 33 (20 de noviembre de 2019): 3142–51. http://dx.doi.org/10.1200/jco.19.00489.
Texto completoGoldinger, Simone M., Carla Murer, Pascale Stieger y Reinhard Dummer. "Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 9071. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9071.
Texto completoPelster, Meredith S. y Rodabe N. Amaria. "Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials". Therapeutic Advances in Medical Oncology 11 (enero de 2019): 175883591983082. http://dx.doi.org/10.1177/1758835919830826.
Texto completoNobre, Liana, Michal Zapotocky, Vijay Ramaswamy, Scott Ryall, Julie Bennett, Julia Balaguer Guill, Lorena Baroni et al. "PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION". Neuro-Oncology 21, Supplement_6 (noviembre de 2019): vi184—vi185. http://dx.doi.org/10.1093/neuonc/noz175.771.
Texto completoHicks, Hannah M., Veronica L. Espinoza, Sharon B. Sams, Nikita Pozdeyev y Rebecca E. Schweppe. "Abstract 2434: The role of a more invasive phenotype in response to MAPK-directed therapies in thyroid cancer". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 2434. http://dx.doi.org/10.1158/1538-7445.am2022-2434.
Texto completoKefford, Richard, Wilson H. Miller, Daniel Shao-Weng Tan, Ryan J. Sullivan, Georgina Long, Rodrigo Dienstmann, Wai Meng David Tai et al. "Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 9029. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9029.
Texto completoRossi, Ernesto, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda et al. "Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma". Biomedicines 11, n.º 2 (29 de enero de 2023): 394. http://dx.doi.org/10.3390/biomedicines11020394.
Texto completoNobre, Liana, Michal Zapotocky, Vijay Ramaswamy, Scott Ryall, Julie Bennet, Daniel Alderete, Julia Balaguer Guill et al. "LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION". Neuro-Oncology 22, Supplement_3 (1 de diciembre de 2020): iii377. http://dx.doi.org/10.1093/neuonc/noaa222.433.
Texto completoMuldoon, Daniel, Guisheng Zhao, Carly Batt, Mallika Singh y Theodore Nicolaides. "MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS". Neuro-Oncology 22, Supplement_3 (1 de diciembre de 2020): iii414. http://dx.doi.org/10.1093/neuonc/noaa222.591.
Texto completoMadej, Ewelina, Anna A. Brożyna, Agnieszka Adamczyk, Norbert Wronski, Agnieszka Harazin-Lechowska, Anna Muzyk, Krzysztof Makuch, Michal Markiewicz, Janusz Rys y Agnieszka Wolnicka-Glubisz. "Vemurafenib and Dabrafenib Downregulates RIPK4 Level". Cancers 15, n.º 3 (1 de febrero de 2023): 918. http://dx.doi.org/10.3390/cancers15030918.
Texto completoUebel, Anne, Stefanie Kewitz-Hempel, Edith Willscher, Kathleen Gebhardt, Cord Sunderkötter y Dennis Gerloff. "Resistance to BRAF Inhibitors: EZH2 and Its Downstream Targets as Potential Therapeutic Options in Melanoma". International Journal of Molecular Sciences 24, n.º 3 (19 de enero de 2023): 1963. http://dx.doi.org/10.3390/ijms24031963.
Texto completoSchreck, Karisa, Andrew Morin, Guisheng Zhao, Bridget Sanford, Adam Green, Kenneth Jones, Anurhada Banerjee et al. "DDRE-13. DECONVOLUTING MECHANISMS OF RESISTANCE TO BRAF INHIBITORS IN BRAF V600E HUMAN GLIOMA". Neuro-Oncology 22, Supplement_2 (noviembre de 2020): ii64. http://dx.doi.org/10.1093/neuonc/noaa215.258.
Texto completoRomano, David, Lucía García-Gutiérrez, Nourhan Aboud, David J. Duffy, Keith T. Flaherty, Dennie T. Frederick, Walter Kolch y David Matallanas. "Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma". Life Science Alliance 5, n.º 10 (29 de agosto de 2022): e202201445. http://dx.doi.org/10.26508/lsa.202201445.
Texto completoThompson, Elizabeth L., Jiayi J. Hu y Laura J. Niedernhofer. "The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma". Cancers 13, n.º 9 (7 de mayo de 2021): 2241. http://dx.doi.org/10.3390/cancers13092241.
Texto completoWattson, Daniel A., Helen Alice Shih, Andrzej Niemierko, Ryan M. Merritt, Donald P. Lawrence, Kevin S. Oh, Ryan J. Sullivan y Keith Flaherty. "Survival patterns following brain metastases for patients with melanoma in the targeted therapy era." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 9064. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9064.
Texto completoČepulytė, Rūta, Andrius Žučenka y Valdas Pečeliūnas. "Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation". Case Reports in Hematology 2020 (15 de octubre de 2020): 1–5. http://dx.doi.org/10.1155/2020/8894031.
Texto completoPark, Robin, Laércio Lopes da Silva, Sunggon Lee y Anwaar Saeed. "Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 3557. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.3557.
Texto completoRöck, Ruth, Johanna E. Mayrhofer, Omar Torres-Quesada, Florian Enzler, Andrea Raffeiner, Philipp Raffeiner, Andreas Feichtner et al. "BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS". Science Advances 5, n.º 8 (agosto de 2019): eaav8463. http://dx.doi.org/10.1126/sciadv.aav8463.
Texto completoKotecha, Rupesh, Jacob A. Miller, Vyshak A. Venur, Alireza M. Mohammadi, Samuel T. Chao, John H. Suh, Gene H. Barnett et al. "Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome". Journal of Neurosurgery 129, n.º 1 (julio de 2018): 50–59. http://dx.doi.org/10.3171/2017.1.jns162797.
Texto completoLeclair, Héloïse M., Nina Tardif, Anaïs Paris, Marie-Dominique Galibert y Sébastien Corre. "Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors". International Journal of Molecular Sciences 21, n.º 14 (16 de julio de 2020): 5025. http://dx.doi.org/10.3390/ijms21145025.
Texto completoDummer, Reinhard, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Reiney Kudchadkar, Carlos Gomez-Roca, Ryan J. Sullivan et al. "Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 9028. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9028.
Texto completoHaselmann, Verena, Christoffer Gebhardt, Ingrid Brechtel, Angelika Duda, Claudia Czerwinski, Antje Sucker, Tim Holland-Letz, Jochen Utikal, Dirk Schadendorf y Michael Neumaier. "Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy". Clinical Chemistry 64, n.º 5 (1 de mayo de 2018): 830–42. http://dx.doi.org/10.1373/clinchem.2017.281543.
Texto completoHuynh, Sandra, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, Olivier Dereure, Marie-Therese Leccia et al. "Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study". Cancers 12, n.º 6 (23 de junio de 2020): 1666. http://dx.doi.org/10.3390/cancers12061666.
Texto completoSwitzer, Benjamin, Sabah Alaklabi, Arya Mariam Roy, Kristopher Attwood, Chong Wang, Lamya Hamad, Tammy Sessanna, Michele Nanni, Yeliam Patel y Igor Puzanov. "Toxicity and outcomes of BRAF and MEK inhibitor “ramp-up” dosing strategies for patients with melanoma: A real-world institutional experience." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e21600-e21600. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21600.
Texto completoSan Lucas, F. Anthony, Scott Kopetz, Paul A. Scheet y Eduardo Vilar Sanchez. "Discovering new targeted therapies for BRAF mutant-like colorectal cancers." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 3623. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3623.
Texto completoPóvoa, Antónia Afonso, Elisabete Teixeira, Maria Rosa Bella-Cueto, Rui Batista, Ana Pestana, Miguel Melo, Thalita Alves et al. "Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma". Cancers 13, n.º 9 (23 de abril de 2021): 2048. http://dx.doi.org/10.3390/cancers13092048.
Texto completoWeber, Jeffrey S., Keith T. Flaherty, Jeffrey R. Infante, Gerald Steven Falchook, Richard Kefford, Adil Daud, Omid Hamid et al. "Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 8510. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8510.
Texto completo